The human rhinovirus: Human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery

Medicinal Research Reviews

Volumn 31, Issue 1, 2011, Pages 42-92

  Rollinger, Judith M ^a   Schmidtke, Michaela ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Antiviral; Common cold; Drug discovery; Rhinovirus

Indexed keywords

2 (3,4 DICHLOROPHENOXY) 5 NITROBENZONITRILE; 4,6 DICHLOROFLAVAN; 6 CHLORO 2 (3,4 DICHLOROPHENOXY) 3,4 DIHYDRO 2H PYRANO[2,3 B]PYRIDINE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIRHINOVIRUS AGENT; ANTITUSSIVE AGENT; ANTIVIRUS AGENT; CAPSID PROTEIN; CFY 196; COLDSOL; DECONGESTIVE AGENT; DISOXARIL; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; IODINE; ISOFLAVAN DERIVATIVE; LOW DENSITY LIPOPROTEIN RECEPTOR; NOSE SPRAY; PIRODAVIR; PLECONARIL; PYROGLUTAMIC ACID; RNA POLYMERASE; RO 09 0081; RO 09 0881; SALICYLIC ACID; SCH 38057; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; VIRUS ANTIBODY; VIRUS RNA;

ABSENTEEISM; ACUTE HEMORRHAGIC CONJUNCTIVITIS; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; APHTHOVIRUS; ASTHMA; BRONCHIOLITIS; CARDIOVIRUS; CELL PROTECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMON COLD; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE TRANSMISSION; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENCEPHALITIS; ENTEROVIRUS; FLACCID PARALYSIS; GASTROENTERITIS; GUILLAIN BARRE SYNDROME; HAND FOOT AND MOUTH DISEASE; HEPATITIS; HEPATITIS A VIRUS; HERPANGINA; HUMAN; HUMAN RHINOVIRUS; KOBUVIRUS; LOWER RESPIRATORY TRACT INFECTION; MEDICAL RESEARCH; MENINGOENCEPHALITIS; MYALGIA; MYOCARDITIS; NONHUMAN; PARECHOVIRUS; PERICARDITIS; PICORNAVIRUS; PNEUMONIA; POLIOMYELITIS; PROTEIN SYNTHESIS; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RHINOVIRUS INFECTION; RNA SYNTHESIS; SEROTYPE; SINUSITIS; STRUCTURE ACTIVITY RELATION; TAXONOMY; TESCHOVIRUS; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VIRAL CONTAMINATION; VIRUS CAPSID; VIRUS CULTURE; VIRUS ENTRY; VIRUS MENINGITIS; VIRUS REPLICATION; VOMITING;

ANTIVIRAL AGENTS; CAPSID PROTEINS; COMMON COLD; GENOME, VIRAL; HUMANS; RHINOVIRUS; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 78649992830     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20176     Document Type: Review

References (359)

1. Le Gall O, Christian P, Fauquet CM, King AM, Knowles NJ, Nakashima N, Stanway G, Gorbalenya AE. Picornavirales, a proposed order of positive-sense single-stranded RNA viruses with a pseudo-T=3 virion architecture. Arch Virol 2008;153:715-727.
2. Briese T, Renwick N, Venter M, Jarman RG, Ghosh D, Kondgen S, Shrestha SK, Hoegh AM, Casas I, Adjogoua EV, Akoua-Koffi C, Myint KS, Williams DT, Chidlow G, van den Berg R, Calvo C, Koch O, Palacios G, Kapoor V, Villari J, Dominguez SR, Holmes KV, Harnett G, Smith D, Mackenzie JS, Ellerbrok H, Schweiger B, Schonning K, Chadha MS, Leendertz FH, Mishra AC, Gibbons RV, Holmes EC, Lipkin WI. Global distribution of novel rhinovirus genotype. Emerg Infect Dis 2008;14:944-947.
3. Kistler AL, Webster DR, Rouskin S, Magrini V, Credle JJ, Schnurr DP, Boushey HA, Mardis ER, Li H, DeRisi JL. Genome-wide diversity and selective pressure in the human rhinovirus. Virol J 2007;4:40.
4. Lau SK, Yip CC, Tsoi HW, Lee RA, So LY, Lau YL, Chan KH, Woo PC, Yuen KY. Clinical features and complete genome characterization of a distinct human rhinovirus (HRV) genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children. J Clin Microbiol 2007;45:3655-3664.
5. McErlean P, Shackelton LA, Lambert SB, Nissen MD, Sloots TP, Mackay IM. Characterisation of a newly identified human rhinovirus, HRV-QPM, discovered in infants with bronchiolitis. J Clin Virol 2007;39:67-75.
6. McErlean P, Shackelton LA, Andrews E, Webster DR, Lambert SB, Nissen MD, Sloots TP, Mackay IM. Distinguishing molecular features and clinical characteristics of a putative new rhinovirus species, human rhinovirus C (HRV C). PLoS ONE 2008;3:e1847.
7. Palmenberg AC, Spiro D, Kuzmickas R, Wang S, Djikeng A, Rathe JA, Fraser-Liggett CM, Liggett SB. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 2009;324:55-59.
8. Oberste MS, Maher K, Flemister MR, Marchetti G, Kilpatrick DR, Pallansch MA. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J Clin Microbiol 2000;38:1170-1174.
9. Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. Molecular evolution of the human enteroviruses: Correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol 1999;73:1941-1948.
10. Oberste MS, Maher K, Kilpatrick DR, Flemister MR, Brown BA, Pallansch MA. Typing of human enteroviruses by partial sequencing of VP1. J Clin Microbiol 1999;37:1288-1293.
11. Horsnell C, Gama RE, Hughes PJ, Stanway G. Molecular relationships between 21 human rhinovirus serotypes. J Gen Virol 1995;76:2549-2555.
12. Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T, Collett MS, Pevear DC. VP1 sequencing of all human rhinovirus serotypes: Insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol 2004;78:3663-3674.
13. Callahan PL, Mizutani S, Colonno RJ. Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14. Proc Natl Acad Sci USA 1985;82:732-736.
14. Duechler M, Skern T, Sommergruber W, Neubauer C, Gruendler P, Fogy I, Blaas D, Kuechler E. Evolutionary relationships within the human rhinovirus genus: Comparison of serotypes 89, 2, and 14. Proc Natl Acad Sci USA 1987;84:2605-2609.
15. Harris JR, Racaniello VR. Amino acid changes in proteins 2B and 3A mediate rhinovirus type 39 growth in mouse cells. J Virol 2005;79:5363-5373.
16. Hughes PJ, North C, Jellis CH, Minor PD, Stanway G. The nucleotide sequence of human rhinovirus 1B: Molecular relationships within the rhinovirus genus. J Gen Virol 1988;69:49-58.
17. Lee WM, Wang W, Rueckert RR. Complete sequence of the RNA genome of human rhinovirus 16, a clinically useful common cold virus belonging to the ICAM-1 receptor group. Virus Genes 1995;9:177-181.
18. Skern T, Sommergruber W, Blaas D, Gruendler P, Fraundorfer F, Pieler C, Fogy I, Kuechler E. Human rhinovirus 2: Complete nucleotide sequence and proteolytic processing signals in the capsid protein region. Nucleic Acids Res 1985;13:2111-2126.
19. Stanway G, Hughes PJ, Mountford RC, Minor PD, Almond JW. The complete nucleotide sequence of a common cold virus: Human rhinovirus 14. Nucleic Acids Res 1984;12:7859-7875.
20. Tapparel C, Junier T, Gerlach D, Cordey S, Van Belle S, Perrin L, Zdobnov EM, Kaiser L. New complete genome sequences of human rhinoviruses shed light on their phylogeny and genomic features. BMC Genomics 2007;8:224.
21. Savolainen C, Blomqvist S, Mulders MN, Hovi T. Genetic clustering of all 102 human rhinovirus prototype strains: Serotype 87 is close to human enterovirus 70. J Gen Virol 2002;83:333-340.
22. Heikkinen T, Jarvinen A. The common cold. Lancet 2003;361:51-59.
23. Savolainen C, Mulders MN, Hovi T. Phylogenetic analysis of rhinovirus isolates collected during successive epidemic seasons. Virus Res 2002;85:41-46.
24. Lee WM, Kiesner C, Pappas T, Lee I, Grindle K, Jartti T, Jakiela B, Lemanske RF, Jr., Shult PA, Gern JE. A diverse group of previously unrecognized human rhinoviruses are common causes of respiratory illnesses in infants. PLoS ONE 2007;2:e966.
25. Peltola V, Waris M, Osterback R, Susi P, Ruuskanen O, Hyypia T. Rhinovirus transmission within families with children: incidence of symptomatic and asymptomatic infections. J Infect Dis 2008;197:382-389.
26. Renwick N, Schweiger B, Kapoor V, Liu Z, Villari J, Bullmann R, Miething R, Briese T, Lipkin WI. A recently identified rhinovirus genotype is associated with severe respiratory-tract infection in children in Germany. J Infect Dis 2007;196:1754-1760.
27. Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993;110:145-160.
28. Puhakka T, Makela MJ, Alanen A, Kallio T, Korsoff L, Arstila P, Leinonen M, Pulkkinen M, Suonpaa J, Mertsola J, Ruuskanen O. Sinusitis in the common cold. J Allergy Clin Immunol 1998;102:403-408.
29. Ruohola A, Waris M, Allander T, Ziegler T, Heikkinen T, Ruuskanen O. Viral etiology of common cold in children, Finland. Emerg Infect Dis 2009;15:344-346.
30. van Gageldonk-Lafeber AB, Heijnen ML, Bartelds AI, Peters MF, van der Plas SM, Wilbrink B. A case-control study of acute respiratory tract infection in general practice patients in The Netherlands. Clin Infect Dis 2005;41:490-497.
31. Versteegh FG, Weverling GJ, Peeters MF, Wilbrink B, Veenstra-van Schie MT, van Leeuwen-Gerritsen JM, Mooi-Kokenberg EA, Schellekens JF, Roord JJ. Community-acquired pathogens associated with prolonged coughing in children: a prospective cohort study. Clin Microbiol Infect 2005;11:801-807.
32. Arruda E, Pitkaranta A, Witek TJ, Jr., Doyle CA, Hayden FG. Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microbiol 1997;35:2864-2868.
33. Makela MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimaki M, Blomqvist S, Hyypia T, Arstila P. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol 1998;36:539-542.
34. Monto AS. The seasonality of rhinovirus infections and its implications for clinical recognition. Clin Ther 2002;24:1987-1997.
35. Zalm MM, van Ewijk BE, Wilbrink B, Uiterwaal CS, Wolfs TF, van der Ent CK. Respiratory pathogens in children with and without respiratory symptoms. J Pediatr 2009;154:396-400.
36. Blomqvist S, Roivainen M, Puhakka T, Kleemola M, Hovi T. Virological and serological analysis of rhinovirus infections during the first two years of life in a cohort of children. J Med Virol 2002;66:263-268.
37. Savolainen-Kopra C, Blomqvist S, Kilpi T, Roivainen M, Hovi T. Novel species of human rhinoviruses in acute otitis media. Pediatr Infect Dis J 2009;28:59-61.
38. El-Sahly HM, Atmar RL, Glezen WP, Greenberg SB. Spectrum of clinical illness in hospitalized patients with "common cold" virus infections. Clin Infect Dis 2000;31:96-100.
39. Garbino J, Gerbase MW, Wunderli W, Kolarova L, Nicod LP, Rochat T, Kaiser L. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest 2004;125:1033-1039.
40. Garbino J, Inoubli S, Mossdorf E, Weber R, Tamm M, Soccal P, Aubert JD, Bridevaux PO, Tapparel C, Kaiser L. Respiratory viruses in HIV-infected patients with suspected respiratory opportunistic infection. AIDS 2008;22:701-705.
41. Gern JE, Calhoun W, Swenson C, Shen G, Busse WW. Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects. Am J Respir Crit Care Med 1997;155:1872-1876.
42. Ghosh S, Champlin R, Couch R, Englund J, Raad I, Malik S, Luna M, Whimbey E. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis 1999;29:528-532.
43. Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003;36:1139-1143.
44. Jacques J, Bouscambert-Duchamp M, Moret H, Carquin J, Brodard V, Lina B, Motte J, Andreoletti L. Association of respiratory picornaviruses with acute bronchiolitis in French infants. J Clin Virol 2006;35:463-466.
45. Kaiser L, Aubert JD, Pache JC, Deffernez C, Rochat T, Garbino J, Wunderli W, Meylan P, Yerly S, Perrin L, Letovanec I, Nicod L, Tapparel C, Soccal PM. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 2006;174:1392-1399.
46. Arruda LK, Sole D, Baena-Cagnani CE, Naspitz CK. Risk factors for asthma and atopy. Curr Opin Allergy Clin Immunol 2005;5:153-159.
47. Grissell TV, Powell H, Shafren DR, Boyle MJ, Hensley MJ, Jones PD, Whitehead BF, Gibson PG. Interleukin-10 gene expression in acute virus-induced asthma. Am J Respir Crit Care Med 2005;172:433-439.
48. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O'Toole S, Myint SH, Tyrrell DA, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-1229.
49. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, Davies DE. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005;201:937-947.
50. Camargo CA, Jr., Ginde AA, Clark S, Cartwright CP, Falsey AR, Niewoehner DE. Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med 2008;3:355-359.
51. McManus TE, Marley AM, Baxter N, Christie SN, O'Neill HJ, Elborn JS, Coyle PV, Kidney JC. Respiratory viral infection in exacerbations of COPD. Respir Med 2008;102:1575-1580.
52. Rohde G, Schlosser B, Arinir U, Kronsbein J, Knoop H, Ringshausen F, Schultze-Werninghaus G. The role of respiratory infections in chronic obstructive pulmonary disease. Med Klin 2007;102:893-898.
53. Schaller M, Hogaboam CM, Lukacs N, Kunkel SL. Respiratory viral infections drive chemokine expression and exacerbate the asthmatic response. J Allergy Clin Immunol 2006;118:295-302.
54. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-1623.
55. Seemungal TA, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000;16:677-683.
56. Crowcroft NS, Zambon M, Harrison TG, Mok Q, Heath P, Miller E. Respiratory syncytial virus infection in infants admitted to paediatric intensive care units in London, and in their families. Eur J Pediatr 2008;167:395-399.
57. Smyth AR, Smyth RL, Tong CY, Hart CA, Heaf DP. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child 1995;73:117-120.
58. Wat D, Gelder C, Hibbitts S, Cafferty F, Bowler I, Pierrepoint M, Evans R, Doull I. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros 2008;7:320-328.
59. Khetsuriani N, Lu X, Teague WG, Kazerouni N, Anderson LJ, Erdman DD. Novel human rhinoviruses and exacerbation of asthma in children. Emerg Infect Dis 2008;14:1793-1796.
60. Miller EK, Edwards KM, Weinberg GA, Iwane MK, Griffin MR, Hall CB, Zhu Y, Szilagyi PG, Morin LL, Heil LH, Lu X, Williams JV. A novel group of rhinoviruses is associated with asthma hospitalizations. J Allergy Clin Immunol 2009;123:98-104.
61. Gwaltney JM, Hendley JO. Rhinovirus transmission: one if by air, two if by hand. Trans Am Clin Climatol Assoc 1978;89:194-200.
62. Musher DM. How contagious are common respiratory tract infections? N Engl J Med 2003;348:1256-1266.
63. Winther B, McCue K, Ashe K, Rubino JR, Hendley JO. Environmental contamination with rhinovirus and transfer to fingers of healthy individuals by daily life activity. J Med Virol 2007;79:1606-1610.
64. Dick EC, Jennings LC, Mink KA, Wartgow CD, Inhorn SL. Aerosol transmission of rhinovirus colds. J Infect Dis 1987;156:442-448.
65. Gwaltney JM, Jr., Moskalski PB, Hendley JO. Hand-to-hand transmission of rhinovirus colds. Ann Intern Med 1978;88:463-467.
66. Gwaltney JM, Jr., Hendley JO. Transmission of experimental rhinovirus infection by contaminated surfaces. Am J Epidemiol 1982;116:828-833.
67. Gwaltney JM, Jr., Moskalski PB, Hendley JO. Interruption of experimental rhinovirus transmission. J Infect Dis 1980;142:811-815.
68. Wutzler P, Sauerbrei A, Klocking R, Brogmann B, Reimer K. Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine. Antiviral Res 2002;54:89-97.
69. Turner RB, Hendley JO. Virucidal hand treatments for prevention of rhinovirus infection. J Antimicrob Chemother 2005;56:805-807.
70. Arruda E, Boyle TR, Winther B, Pevear DC, Gwaltney JM, Jr., Hayden FG. Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J Infect Dis 1995;171:1329-1333.
71. Bardin PG, Sanderson G, Robinson BS, Holgate ST, Tyrrell DA. Experimental rhinovirus infection in volunteers. Eur Respir J 1996;9:2250-2255.
72. Gern JE, Galagan DM, Jarjour NN, Dick EC, Busse WW. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med 1997;155:1159-1161.
73. Gern JE, Vrtis R, Grindle KA, Swenson C, Busse WW. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med 2000;162:2226-2231.
74. Winther B, Farr B, Turner RB, Hendley JO, Gwaltney JM, Jr., Mygind N. Histopathologic examination and enumeration of polymorphonuclear leukocytes in the nasal mucosa during experimental rhinovirus colds. Acta Otolaryngol Suppl 1984;413:19-24.
75. Winther B, Gwaltney JM, Jr., Mygind N, Turner RB, Hendley JO. Sites of rhinovirus recovery after point inoculation of the upper airway. JAMA 1986;256:1763-1767.
76. Harris 2nd JM, Gwaltney JM, Jr. Incubation periods of experimental rhinovirus infection and illness. Clin Infect Dis 1996;23:1287-1290.
77. Mosser AG, Vrtis R, Burchell L, Lee WM, Dick CR, Weisshaar E, Bock D, Swenson CA, Cornwell RD, Meyer KC, Jarjour NN, Busse WW, Gern JE. Quantitative and qualitative analysis of rhinovirus infection in bronchial tissues. Am J Respir Crit Care Med 2005;171:645-651.
78. Papadopoulos NG, Bates PJ, Bardin PG, Papi A, Leir SH, Fraenkel DJ, Meyer J, Lackie PM, Sanderson G, Holgate ST, Johnston SL. Rhinoviruses infect the lower airways. J Infect Dis 2000;181:1875-1884.
79. Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RT, Werno AM, Young SA, Chambers ST, Murdoch DR. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008;63:42-48.
80. Juven T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, Eskola J, Saikku P, Ruuskanen O. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000;19:293-298.
81. Templeton KE, Scheltinga SA, van den Eeden WC, Graffelman AW, van den Broek PJ, Claas EC. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005;41:345-351.
82. Tsolia MN, Psarras S, Bossios A, Audi H, Paldanius M, Gourgiotis D, Kallergi K, Kafetzis DA, Constantopoulos A, Papadopoulos NG. Etiology of community-acquired pneumonia in hospitalized school-age children: Evidence for high prevalence of viral infections. Clin Infect Dis 2004;39:681-686.
83. Turner RB, Weingand KW, Yeh CH, Leedy DW. Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds. Clin Infect Dis 1998;26:840-846.
84. Pappas DE, Hendley JO, Hayden FG, Winther B. Symptom profile of common colds in school-aged children. Pediatr Infect Dis J 2008;27:8-11.
85. Gwaltney JM, Jr., Scheld WM, Sande MA, Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: A fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 1992;90:457-462.
86. Lehtinen P, Jartti T, Virkki R, Vuorinen T, Leinonen M, Peltola V, Ruohola A, Ruuskanen O. Bacterial coinfections in children with viral wheezing. Eur J Clin Microbiol Infect Dis 2006;25:463-469.
87. Bardin PG, Fraenkel DJ, Sanderson G, Dorward M, Lau LC, Johnston SL, Holgate ST. Amplified rhinovirus colds in atopic subjects. Clin Exp Allergy 1994;24:457-464.
88. Calhoun WJ, Swenson CA, Dick EC, Schwartz LB, Lemanske RF, Jr., Busse WW. Experimental rhinovirus 16 infection potentiates histamine release after antigen bronchoprovocation in allergic subjects. Am Rev Respir Dis 1991;144:1267-1273.
89. Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med 1995;151:879-886.
90. Gern JE, Busse WW. The effects of rhinovirus infections on allergic airway responses. Am J Respir Crit Care Med 1995;152:S40-S45.
91. Lemanske RF, Jr., Dick EC, Swenson CA, Vrtis RF, Busse WW. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 1989;83:1-10.
92. Mallia P, Message SD, Kebadze T, Parker HL, Kon OM, Johnston SL. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: A pilot study. Respir Res 2006;7:116.
93. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, Contoli M, Sanderson G, Kon OM, Papi A, Jeffery PK, Stanciu LA, Johnston SL. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 2008;105:13562-13567.
94. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003;163:487-494.
95. Patick AK. Rhinovirus chemotherapy. Antiviral Res 2006;71:391-396.
96. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001;33:757-762.
97. Hayden FG. Influenza virus and rhinovirus-related otitis media: Potential for antiviral intervention. Vaccine 2000;19:S66-S70.
98. Racaniello VR. Picornaviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology, 5th ed. Volume 1. Philadelphia: Lippincott Williams & Wilkins; 2007. pp 796-839.
99. Arnold E, Rossmann MG. Analysis of the structure of a common cold virus, human rhinovirus 14, refined at a resolution of 3.0 A. J Mol Biol 1990;211:763-801.
100. Hadfield AT, Lee W, Zhao R, Oliveira MA, Minor I, Rueckert RR, Rossmann MG. The refined structure of human rhinovirus 16 at 2.15 A resolution: Implications for the viral life cycle. Structure 1997;5:427-441.
101. Kim SS, Smith TJ, Chapman MS, Rossmann MC, Pevear DC, Dutko FJ, Felock PJ, Diana GD, McKinlay MA. Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol 1989;210:91-111.
102. Oliveira MA, Zhao R, Lee WM, Kremer MJ, Minor I, Rueckert RR, Diana GD, Pevear DC, Dutko FJ, McKinlay MA, et al. The structure of human rhinovirus 16. Structure 1993;1:51-68.
103. Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG, et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985;317:145-153.
104. Verdaguer N, Blaas D, Fita I. Structure of human rhinovirus serotype 2 (HRV2). J Mol Biol 2000;300:1179-1194.
105. Zhao R, Pevear DC, Kremer MJ, Giranda VL, Kofron JA, Kuhn RJ, Rossmann MG. Human rhinovirus 3 at 3.0 A resolution. Structure 1996;4:1205-1220.
106. Rossmann MG. The canyon hypothesis. Viral Immunol 1989;2:143-161.
107. Rossmann MG. Viral cell recognition and entry. Protein Sci 1994;3:1712-1725.
108. Rossmann MG, Olson NH, Kolatkar PR, Oliveira MA, Cheng RH, Greve JM, McClelland A, Baker TS. Crystallographic and cryo EM analysis of virion-receptor interactions. Arch Virol Suppl 1994;9:531-541.
109. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989;56:849-853.
110. Vlasak M, Roivainen M, Reithmayer M, Goesler I, Laine P, Snyers L, Hovi T, Blaas D. The minor receptor group of human rhinovirus (HRV) includes HRV23 and HRV25, but the presence of a lysine in the VP1 HI loop is not sufficient for receptor binding. J Virol 2005;79:7389-7395.
111. Hofer F, Gruenberger M, Kowalski H, Machat H, Huettinger M, Kuechler E, Blaas D. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc Natl Acad Sci USA 1994;91:1839-1842.
112. Rankl C, Kienberger F, Wildling L, Wruss J, Gruber Hermann J, Blaas D, Hinterdorfer P. Multiple receptors involved in human rhinovirus attachment to live cells. Proc Natl Acad Sci USA 2008;105:17778-17783.
113. Kolatkar PR, Bella J, Olson NH, Bator CM, Baker TS, Rossmann MG. Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor. EMBO J 1999;18:6249-6259.
114. Hewat EA, Neumann E, Conway JF, Moser R, Ronacher B, Marlovits TC, Blaas D. The cellular receptor to human rhinovirus 2 binds around the 5-fold axis and not in the canyon: A structural view. EMBO J 2000;19:6317-6325.
115. Uncapher CR, DeWitt CM, Colonno RJ. The major and minor group receptor families contain all but one human rhinovirus serotype. Virology 1991;180:814-817.
116. Khan AG, Pichler J, Rosemann A, Blaas D. Human rhinovirus type 54 infection via heparan sulfate is less efficient and strictly dependent on low endosomal pH. J Virol 2007;81:4625-4632.
117. Vlasak M, Goesler I, Blaas D. Human rhinovirus type 89 variants use heparan sulfate proteoglycan for cell attachment. J Virol 2005;79:5963-5970.
118. Grunert HP, Wolf KU, Langner KD, Sawitzky D, Habermehl KO, Zeichhardt H. Internalization of human rhinovirus 14 into HeLa and ICAM-1-transfected BHK cells. Med Microbiol Immunol 1997;186:1-9.
119. Reischl A, Reithmayer M, Winsauer G, Moser R, Gosler I, Blaas D. Viral evolution toward change in receptor usage: Adaptation of a major group human rhinovirus to grow in ICAM-1-negative cells. J Virol 2001;75:9312-9319.
120. Zauner W, Blaas D, Kuechler E, Wagner E. Rhinovirus-mediated endosomal release of transfection complexes. J Virol 1995;69:1085-1092.
121. Schober D, Kronenberger P, Prchla E, Blaas D, Fuchs R. Major and minor receptor group human rhinoviruses penetrate from endosomes by different mechanisms. J Virol 1998;72:1354-1364.
122. Hewat EA, Blaas D. Cryoelectron microscopy analysis of the structural changes associated with human rhinovirus type 14 uncoating. J Virol 2004;78:2935-2942.
123. Hoover-Litty H, Greve JM. Formation of rhinovirus-soluble ICAM-1 complexes and conformational changes in the virion. J Virol 1993;67:390-397.
124. Brabec M, Baravalle G, Blaas D, Fuchs R. Conformational changes, plasma membrane penetration, and infection by human rhinovirus type 2: Role of receptors and low pH. J Virol 2003;77:5370-5377.
125. Prchla E, Kuechler E, Blaas D, Fuchs R. Uncoating of human rhinovirus serotype 2 from late endosomes. J Virol 1994;68:3713-3723.
126. Verdaguer N, Fita I, Reithmayer M, Moser R, Blaas D. X-ray structure of a minor group human rhinovirus bound to a fragment of its cellular receptor protein. Nat Struct Mol Biol 2004;11:429-434.
127. Knott JA, Orr DC, Montgomery DS, Sullivan CA, Weston A. The expression and purification of human rhinovirus protease 3C. Eur J Biochem 1989;182:547-555.
128. Sommergruber W, Zorn M, Blaas D, Fessl F, Volkmann P, Maurer-Fogy I, Pallai P, Merluzzi V, Matteo M, Skern T, et al. Polypeptide 2A of human rhinovirus type 2: Identification as a protease and characterization by mutational analysis. Virology 1989;169:68-77.
129. Haghighat A, Svitkin Y, Novoa I, Kuechler E, Skern T, Sonenberg N. The eIF4G-eIF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase. J Virol 1996;70:8444-8450.
130. Liebig HD, Ziegler E, Yan R, Hartmuth K, Klump H, Kowalski H, Blaas D, Sommergruber W, Frasel L, Lamphear B, et al. Purification of two picornaviral 2A proteinases: Interaction with eIF-4 gamma and influence on in vitro translation. Biochemistry 1993;32:7581-7588.
131. Sommergruber W, Ahorn H, Klump H, Seipelt J, Zoephel A, Fessl F, Krystek E, Blaas D, Kuechler E, Liebig HD, et al. 2A proteinases of coxsackie-and rhinovirus cleave peptides derived from eIF-4 gamma via a common recognition motif. Virology 1994;198:741-745.
132. Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador 3rd JW, Matthews DA, Patick AK. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 2005;49:619-626.
133. Turner RB, Couch RB. Rhinoviruses. In: Knipe DM, Howley PM, editors. Fields virology, 5th ed. Volume 1. Philadelphia: Lippincott Williams & Wilkins; 2007. pp 895-909.
134. Ghildyal R, Dagher H, Donninger H, de Silva D, Li X, Freezer NJ, Wilson JW, Bardin PG. Rhinovirus infects primary human airway fibroblasts and induces a neutrophil chemokine and a permeability factor. J Med Virol 2005;75:608-615.
135. Jakiela B, Brockman-Schneider R, Amineva S, Lee WM, Gern JE. Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. Am J Respir Cell Mol Biol 2008;38:517-523.
136. Lopez-Souza N, Dolganov G, Dubin R, Sachs LA, Sassina L, Sporer H, Yagi S, Schnurr D, Boushey HA, Widdicombe JH. Resistance of differentiated human airway epithelium to infection by rhinovirus. Am J Physiol 2004;286:L373-L381.
137. Conti C, Orsi N, Stein ML. Effect of isoflavans and isoflavenes on rhinovirus 1B and its replication in HeLa cells. Antiviral Res 1988;10:117-127.
138. Diana GD, Otto MJ, Treasurywala AM, McKinlay MA, Oglesby RC, Maliski EG, Rossmann MG, Smith TJ. Enantiomeric effects of homologues of disoxaril on the inhibitory activity against human rhinovirus-14. J Med Chem 1988;31:540-544.
139. Otto MJ, Fox MP, Fancher MJ, Kuhrt MF, Diana GD, McKinlay MA. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother 1985;27:883-886.
140. Andries K, Dewindt B, Snoeks J, Wouters L, Moereels H, Lewi PJ, Janssen PA. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J Virol 1990;64:1117-1123.
141. Watson KG, Brown RN, Cameron R, Chalmers DK, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell DB, Reece PA, Ryan J, Stanislawski PC, Tucker SP, Wu WY, Barnard DL, Sidwell RW. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J Med Chem 2003;46:3181-3184.
142. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother 2004;48:1766-1772.
143. Makarov VA, Riabova OB, Granik VG, Wutzler P, Schmidtke M. Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. J Antimicrob Chemother 2005;55:483-488.
144. Rollinger JM, Steindl TM, Schuster D, Kirchmair J, Anrain K, Ellmerer EP, Langer T, Stuppner H, Wutzler P, Schmidtke M. Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. J Med Chem 2008;51:842-851.
145. Binford SL, Weady PT, Maldonado F, Brothers MA, Matthews DA, Patick AK. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 2007;51:4366-4373.
146. Yin FH, Lomax NB. Establishment of a mouse model for human rhinovirus infection. J Gen Virol 1986;67:2335-2340.
147. Newcomb DC, Sajjan US, Nagarkar DR, Wang Q, Nanua S, Zhou Y, McHenry CL, Hennrick KT, Tsai WC, Bentley JK, Lukacs NW, Johnston SL, Hershenson MB. Human rhinovirus 1B exposure induces phosphatidylinositol 3-kinase-dependent airway inflammation in mice. Am J Respir Crit Care Med 2008;177:1111-1121.
148. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, Glanville N, Choy KJ, Jourdan P, Burnet J, Tuthill TJ, Pedrick MS, Hurle MJ, Plumpton C, Sharp NA, Bussell JN, Swallow DM, Schwarze J, Guy B, Almond JW, Jeffery PK, Lloyd CM, Papi A, Killington RA, Rowlands DJ, Blair ED, Clarke NJ, Johnston SL. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 2008;14:199-204.
149. Hayden FG, Gwaltney JM, Jr. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother 1982;21:892-897.
150. Hayden FG, Gwaltney JM, Jr. Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. J Infect Dis 1984;150:174-180.
151. Levandowski RA, Pachucki CT, Rubenis M, Jackson GG. Topical enviroxime against rhinovirus infection. Antimicrob Agents Chemother 1982;22:1004-1007.
152. Phillpotts RJ, Wallace J, Tyrrell DA, Tagart VB. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother 1983;23:671-675.
153. Turner RB, Dutko FJ, Goldstein NH, Lockwood G, Hayden FG. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother 1993;37:297-300.
154. Turner RB, Riker DK, Gangemi JD. Ineffectiveness of echinacea for prevention of experimental rhinovirus colds. Antimicrob Agents Chemother 2000;44:1708-1709.
155. Barnard DL. Current status of anti-picornavirus therapies. Curr Pharm Des 2006;12:1379-1390.
156. De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med Res Rev 2008;28:823-884.
157. Lall MS, Jain RP, Vederas JC. Inhibitors of 3C cysteine proteinases from Picornaviridae. Curr Top Med Chem 2004;4:1239-1253.
158. Colonno RJ, Callahan PL, Long WJ. Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J Virol 1986;57:7-12.
159. Hodits RA, Nimpf J, Pfistermueller DM, Hiesberger T, Schneider WJ, Vaughan TJ, Johnson KS, Haumer M, Kuechler E, Winter G, et al. An antibody fragment from a phage display library competes for ligand binding to the low density lipoprotein receptor family and inhibits rhinovirus infection. J Biol Chem 1995;270:24078-24085.
160. Hayden FG, Gwaltney JM, Jr., Colonno RJ. Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res 1988;9:233-247.
161. Fang F, Yu M. Viral receptor blockage by multivalent recombinant antibody fusion proteins: Inhibiting human rhinovirus (HRV) infection with CFY196. J Antimicrob Chemother 2004;53:23-25.
162. Crump CE, Arruda E, Hayden FG. Comparative antirhinoviral activities of soluble intercellular adhesion molecule-1 (sICAM-1) and chimeric ICAM-1/immunoglobulin A molecule. Antimicrob Agents Chemother 1994;38:1425-1427.
163. Marlin SD, Staunton DE, Springer TA, Stratowa C, Sommergruber W, Merluzzi VJ. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 1990;344:70-72.
164. Ohlin A, Hoover-Litty H, Sanderson G, Paessens A, Johnston SL, Holgate ST, Huguenel E, Greve JM. Spectrum of activity of soluble intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates. Antimicrob Agents Chemother 1994;38:1413-1415.
165. Marlovits TC, Abrahamsberg C, Blaas D. Soluble LDL minireceptors. Minimal structure requirements for recognition of minor group human rhinovirus. J Biol Chem 1998;273:33835-33840.
166. Moser R, Snyers L, Wruss J, Angulo J, Peters H, Peters T, Blaas D. Neutralization of a common cold virus by concatemers of the third ligand binding module of the VLDL-receptor strongly depends on the number of modules. Virology 2005;338:259-269.
167. Nicodemou A, Petsch M, Konecsni T, Kremser L, Kenndler E, Casasnovas JM, Blaas D. Rhinovirus-stabilizing activity of artificial VLDL-receptor variants defines a new mechanism for virus neutralization by soluble receptors. FEBS Lett 2005;579:5507-5511.
168. Arruda E, Crump CE, Marlin SD, Merluzzi VJ, Hayden FG. In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1. Antimicrob Agents Chemother 1992;36:1186-1191.
169. Greve JM, Forte CP, Marlor CW, Meyer AM, Hoover-Litty H, Wunderlich D, McClelland A. Mechanisms of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. J Virol 1991;65:6015-6023.
170. Martin S, Casasnovas JM, Staunton DE, Springer TA. Efficient neutralization and disruption of rhinovirus by chimeric ICAM-1/immunoglobulin molecules. J Virol 1993;67:3561-3568.
171. Marlovits TC, Zechmeister T, Gruenberger M, Ronacher B, Schwihla H, Blaas D. Recombinant soluble low density lipoprotein receptor fragment inhibits minor group rhinovirus infection in vitro. FASEB J 1998;12:695-703.
172. Huguenel ED, Cohn D, Dockum DP, Greve JM, Fournel MA, Hammond L, Irwin R, Mahoney J, McClelland A, Muchmore E, Ohlin AC, Scuderi P. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1. Am J Respir Crit Care Med 1997;155:1206-1210.
173. Turner RB, Wecker MT, Pohl G, Witek TJ, McNally E, St George R, Winther B, Hayden FG. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: A randomized clinical trial. J Am Med Assoc 1999;281:1797-1804.
174. Diana GD. Inhibitors of picornavirus replication. Curr Med Chem 2003;2:1-12.
175. Rossmann MG. The structure of antiviral agents that inhibit uncoating when complexed with viral capsids. Antiviral Res 1989;11:3-13.
176. Zhang Y, Simpson AA, Ledford RM, Bator CM, Chakravarty S, Skochko GA, Demenczuk TM, Watanyar A, Pevear DC, Rossmann MG. Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds. J Virol 2004;78:11061-11069.
177. Badger J, Minor I, Oliveira MA, Smith TJ, Rossmann MG. Structural analysis of antiviral agents that interact with the capsid of human rhinoviruses. Proteins 1989;6:1-19.
178. Pevear DC, Fancher MJ, Felock PJ, Rossmann MG, Miller MS, Diana G, Treasurywala AM, McKinlay MA, Dutko FJ. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol 1989;63:2002-2007.
179. Smith TJ, Kremer MJ, Luo M, Vriend G, Arnold E, Kamer G, Rossmann MG, McKinlay MA, Diana GD, Otto MJ. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 1986;233:1286-1293.
180. Kim KH, Willingmann P, Gong ZX, Kremer MJ, Chapman MS, Minor I, Oliveira MA, Rossmann MG, Andries K, Diana GD, et al. A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J Mol Biol 1993;230:206-227.
181. Hadfield AT, Diana GD, Rossmann MG. Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16. Proc Natl Acad Sci USA 1999;96:14730-14735.
182. Dewindt B, van Eemeren K, Andries K. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses. Antiviral Res 1994;25:67-72.
183. Kaiser L, Crump CE, Hayden FG. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res 2000;47:215-220.
184. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999;43:2109-2115.
185. Schmidtke M, Hammerschmidt E, Schuler S, Zell R, Birch-Hirschfeld E, Makarov VA, Riabova OB, Wutzler P. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: Antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother 2005;56:648-656.
186. Andries K, Dewindt B, De Brabander M, Stokbroekx R, Janssen PA. In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol 1988;101:155-167.
187. Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother 1992;36:100-107.
188. Kuz'min VE, Artemenko AG, Muratov EN, Volineckaya IL, Makarov VA, Riabova OB, Wutzler P, Schmidtke M. Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication. J Med Chem 2007;50:4205-4213.
189. Buontempo PJ, Cox S, Wright-Minogue J, DeMartino JL, Skelton AM, Ferrari E, Albin R, Rozhon EJ, Girijavallabhan V, Modlin JF, O'Connell JF. SCH 48973: A potent, broad-spectrum, antienterovirus compound. Antimicrob Agents Chemother 1997;41:1220-1225.
190. Cox S, Buontempo PJ, Wright-Minogue J, DeMartino JL, Skelton AM, Ferrari E, Schwartz J, Rozhon EJ, Linn CC, Girijavallabhan V, O'Connell JF. Antipicornavirus activity of SCH 47802 and analogs: In vitro and in vivo studies. Antiviral Res 1996;32:71-79.
191. Rozhon E, Cox S, Buontempo P, O'Connell J, Slater W, De Martino J, Schwartz J, Miller G, Arnold E, Zhang A, et al. SCH 38057: A picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res 1993;21:15-35.
192. Ishitsuka H, Ninomiya YT, Ohsawa C, Fujiu M, Suhara Y. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410. Antimicrob Agents Chemother 1982;22:617-621.
193. Ninomiya Y, Shimma N, Ishitsuka H. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid-binding agents, chalcone amides. Antiviral Res 1990;13:61-74.
194. Bauer DJ, Selway JW, Batchelor JF, Tisdale M, Caldwell IC, Young DA. 4′, 6-Dichloroflavan (BW683C), a new anti-rhinovirus compound. Nature 1981;292:369-370.
195. Bargar TM, Dulworth JK, Kenny MT, Massad R, Daniel JK, Wilson T, Sargent RN. 3, 4-Dihydro-2-phenyl-2H-pyrano[2, 3-b]pyridines with potent antirhinovirus activity. J Med Chem 1986;29:1590-1595.
196. Kenny MT, Dulworth JK, Bargar TM, Torney HL, Graham MC, Manelli AM. In vitro antiviral activity of the 6-substituted 2-(3′, 4′-dichlorophenoxy)-2H-pyrano[2, 3-b]pyridines MDL 20, 610, MDL 20, 646, and MDL 20, 957. Antimicrob Agents Chemother 1986;30:516-518.
197. Markley LD, Tong YC, Dulworth JK, Steward DL, Goralski CT, Johnston H, Wood SG, Vinogradoff AP, Bargar TM. Antipicornavirus activity of substituted phenoxybenzenes and phenoxypyridines. J Med Chem 1986;29:427-433.
198. Powers RD, Gwaltney JM, Jr., Hayden FG. Activity of 2-(3, 4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro. Antimicrob Agents Chemother 1982;22:639-642.
199. Rossmann MG, McKinlay MA. Application of crystallography to the design of antiviral agents. Infect Agents Dis 1992;1:3-10.
200. Schiff GM, Sherwood JR. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis 2000;181:20-26.
201. Hayden FG, Coats T, Kim K, Hassman HA, Blatter MM, Zhang B, Liu S. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: Efficacy and tolerability in phase II clinical trials. Antivir Ther 2002;7:53-65.
202. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003;36:1523-1532.
203. Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother 2005;49:4492-4499.
204. Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS, Jr. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol 2006;46:103-108.
205. Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 1992;36:727-732.
206. Krenn BM, Holzer B, Gaudernak E, Triendl A, van Kuppeveld FJ, Seipelt J. Inhibition of polyprotein processing and RNA replication of human rhinovirus by pyrrolidine dithiocarbamate involves metal ions. J Virol 2005;79:13892-13899.
207. Badorff C, Fichtlscherer B, Rhoads RE, Zeiher AM, Muelsch A, Dimmeler S, Knowlton KU. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy. Circulation 2000;102:2276-2281.
208. Saura M, Zaragoza C, McMillan A, Quick RA, Hohenadl C, Lowenstein JM, Lowenstein CJ. An antiviral mechanism of nitric oxide: Inhibition of a viral protease. Immunity 1999;10:21-28.
209. Zaragoza C, Ocampo CJ, Saura M, McMillan A, Lowenstein CJ. Nitric oxide inhibition of coxsackievirus replication in vitro. J Clin Invest 1997;100:1760-1767.
210. Zell R, Markgraf R, Schmidtke M, Gorlach M, Stelzner A, Henke A, Sigusch HH, Gluck B. Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. Med Microbiol Immunol 2004;193:91-100.
211. Kaul P, Singh I, Turner RB. Effect of nitric oxide on rhinovirus replication and virus-induced interleukin-8 elaboration. Am J Respir Crit Care Med 1999;159:1193-1198.
212. Molla A, Hellen CU, Wimmer E. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J Virol 1993;67:4688-4695.
213. Deszcz L, Cencic R, Sousa C, Kuechler E, Skern T. An antiviral peptide inhibitor that is active against picornavirus 2A proteinases but not cellular caspases. J Virol 2006;80:9619-9627.
214. Deszcz L, Seipelt J, Vassilieva E, Roetzer A, Kuechler E. Antiviral activity of caspase inhibitors: Effect on picornaviral 2A proteinase. FEBS Lett 2004;560:51-55.
215. Wang QM, Johnson RB, Jungheim LN, Cohen JD, Villarreal EC. Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides. Antimicrob Agents Chemother 1998;42:916-920.
216. Matthews DA, Smith WW, Ferre RA, Condon B, Budahazi G, Sisson W, Villafranca JE, Janson CA, McElroy HE, Gribskov CL, et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 1994;77:761-771.
217. Kuo C-J, Liu H-G, Lo Y-K, Seong C-M, Lee K-I, Jung Y-S, Liang P-H. Individual and common inhibitors of coronavirus and picornavirus main proteases. FEBS Lett 2009;583:549-555.
218. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, Delisle DM, Worland ST. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 1999;96:11000-11007.
219. Maugeri C, Alisi MA, Apicella C, Cellai L, Dragone P, Fioravanzo E, Florio S, Furlotti G, Mangano G, Ombrato R, Luisi R, Pompei R, Rincicotti V, Russo V, Vitiello M, Cazzolla N. New anti-viral drugs for the treatment of the common cold. Bioorg Med Chem 2008;16:3091-3107.
220. Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador 3rd JW, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem 1998;41:2806-2818.
221. Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Reich SH, Marakovits JT, Prins TJ, Zhou R, Tikhe J, Littlefield ES, Bleckman TM, Wallace MB, Little TL, Ford CE, Meador 3rd JW, Ferre RA, Brown EL, Binford SL, DeLisle DM, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J Med Chem 1998;41:2819-2834.
222. Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson JP, Sakata SK, Chen L, Guzman MC, Meador 3rd JW, Ferre RA, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. J Med Chem 2002;45:1607-1623.
223. Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Meador 3rd JW, Ferre RA, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem 1999;42:1203-1212.
224. Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: Structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics. Bioorg Med Chem Lett 2002;12:733-738.
225. Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador 3rd JW, Ferre RA. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem 2003;46:4572-4585.
226. Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador 3rd JW, Ferre RA, Harr JE, Kosa MB, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem 1999;42:1213-1224.
227. Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 1999;43:2444-2450.
228. Zalman LS, Brothers MA, Dragovich PS, Zhou R, Prins TJ, Worland ST, Patick AK. Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 2000;44:1236-1241.
229. Hsyu PH, Pithavala YK, Gersten M, Penning CA, Kerr BM. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob Agents Chemother 2002;46:392-397.
230. Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, Patick AK, Smith 3rd GJ, Zalman LS. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 2003;47:3907-3916.
231. Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith 3rd GJ, Zalman LS, Burns-Naas LA, Tran JQ. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 2005;49:2267-2275.
232. Schubert S, Furste JP, Werk D, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J. Gaining target access for deoxyribozymes. J Mol Biol 2004;339:355-363.
233. Stone JK, Rijnbrand R, Stein DA, Ma Y, Yang Y, Iversen PL, Andino R. A morpholino oligomer targeting highly conserved internal ribosome entry site sequence is able to inhibit multiple species of picornavirus. Antimicrob Agents Chemother 2008;52:1970-1981.
234. Phipps KM, Martinez A, Lu J, Heinz BA, Zhao G. Small interfering RNA molecules as potential anti-human rhinovirus agents: In vitro potency, specificity, and mechanism. Antiviral Res 2004;61:49-55.
235. Verheyden B, Andries K, Rombaut B. Mode of action of 2-furylmercury chloride, an anti-rhinovirus compound. Antiviral Res 2004;61:189-194.
236. Van Hoof L, Vanden Berghe DA, Hatfield GM, Vlietinck AJ. Plant antiviral agents; V. 3-Methoxyflavones as potent inhibitors of viral-induced block of cell synthesis. Planta Med 1984;50:513-517.
237. Gaudernak E, Seipelt J, Triendl A, Grassauer A, Kuechler E. Antiviral effects of pyrrolidine dithiocarbamate on human rhinoviruses. J Virol 2002;76:6004-6015.
238. De Clercq E, Murase J, Marquez VE. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem Pharmacol 1991;41:1821-1829.
239. Andersen DO, Murray BK, Robins RK, North JA. In vitro antiviral activity of ribavirin against picornaviruses. Antivir Chem Chemother 1992;6:361-370.
240. De Clercq E. Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives. Med Res Rev 2009;29:611-645.
241. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-1379.
242. Reyes GR. Ribavirin: Recent insights into antiviral mechanisms of action. Curr Opin Drug Disc 2001;4:651-656.
243. DeLong DC, Reed SE. Inhibition of rhinovirus replication in in organ culture by a potential antiviral drug. J Infect Dis 1980;141:87-91.
244. Wikel JH, Paget CJ, DeLong DC, Nelson JD, Wu CY, Paschal JW, Dinner A, Templeton RJ, Chaney MO, Jones ND, Chamberlin JW. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J Med Chem 1980;23:368-372.
245. Ninomiya Y, Aoyama M, Umeda I, Suhara Y, Ishitsuka H. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15, 731, 4′, 6-dichloroflavan, and enviroxime. Antimicrob Agents Chemother 1985;27:595-599.
246. Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol 1995;69:4189-4197.
247. Heinz BA, Vance LM. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J Virol 1996;70:4854-4857.
248. Brown-Augsburger P, Vance LM, Malcolm SK, Hsiung H, Smith DP, Heinz BA. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch Virol 1999;144:1569-1585.
249. Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER, Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother 1985;27:102-106.
250. Phillpotts RJ, Jones RW, Delong DC, Reed SE, Wallace J, Tyrrell DA. The activity of enviroxime against rhinovirus infection in man. Lancet 1981;1:1342-1344.
251. Wyde PR, Six HR, Wilson SZ, Gilbert BE, Knight V. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother 1988;32:890-895.
252. Hamdouchi C, de Blas J, del Prado M, Gruber J, Heinz BA, Vance L. 2-Amino-3-substituted-6-[(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl]imid azo[1, 2-a]pyridines as a novel class of inhibitors of human rhinovirus: Stereospecific synthesis and antiviral activity. J Med Chem 1999;42:50-59.
253. Hamdouchi C, Ezquerra J, Vega JA, Vaquero JJ, Alvarez-Builla J, Heinz BA. Short synthesis and anti-rhinoviral activity of imidazo[1, 2-a]pyridines: The effect of acyl groups at 3-position. Bioorg Med Chem Lett 1999;9:1391-1394.
254. Victor F, Brown TJ, Campanale K, Heinz BA, Shipley LA, Su KS, Tang J, Vance LM, Spitzer WA. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. J Med Chem 1997;40:1511-1518.
255. Victor F, Loncharich R, Tang J, Spitzer WA. Synthesis and antiviral activity of C2 analogs of enviroxime: An exploration of the role of critical functionality. J Med Chem 1997;40:3478-3483.
256. Came PE, Schafer TW, Silver GH. Sensitivity of rhinoviruses to human leukocyte and fibroblast interferons. J Infect Dis 1976;133:A136-A139.
257. Kramer MJ, Dennin R, Kramer C, Jones G, Connell E, Rolon N, Gruarin A, Kale R, Trown PW. Cell and virus sensitivity studies with recombinant human alpha interferons. J Interferon Res 1983;3:425-435.
258. Sperber SJ, Hayden FG. Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta. J Interferon Res 1989;9:285-293.
259. Farr BM, Gwaltney JM, Jr., Adams KF, Hayden FG. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother 1984;26:31-34.
260. Hayden FG, Gwaltney JM, Jr. Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis 1983;148:543-550.
261. Higgins PG, Al-Nakib W, Willman J, Tyrrell DA. Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers. J Interferon Res 1986;6:153-159.
262. Phillpotts RJ, Scott GM, Higgins PG, Wallace J, Tyrrell DA, Gauci CL. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2. Antiviral Res 1983;3:121-136.
263. Samo TC, Greenberg SB, Couch RB, Quarles J, Johnson PE, Hook S, Harmon MW. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis 1983;148:535-542.
264. Samo TC, Greenberg SB, Palmer JM, Couch RB, Harmon MW, Johnson PE. Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose. J Infect Dis 1984;150:181-188.
265. Higgins PG, Al-Nakib W, Barrow GI, Tyrrell DA. Recombinant human interferon-gamma as prophylaxis against rhinovirus colds in volunteers. J Interferon Res 1988;8:591-596.
266. Monto AS, Schwartz SA, Albrecht JK. Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families. Antimicrob Agents Chemother 1989;33:387-390.
267. Farr BM, Gwaltney JM, Jr., Hendley JO, Hayden FG, Naclerio RM, McBride T, Doyle WJ, Sorrentino JV, Riker DK, Proud D. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis 1990;162:1173-1177.
268. Ahmad AL, Tyrrell DA. Synergism between anti-rhinovirus antivirals: Various human interferons and a number of synthetic compounds. Antiviral Res 1986;6:241-252.
269. Higgins PG, Barrow GI, Al-Nakib W, Tyrrell DA, DeLong DC, Lenox-Smith I. Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers. Antiviral Res 1988;10:141-149.
270. Feher M, Schmidt JM. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2003;43:218-227.
271. Zheng S, Luo X, Chen G, Zhu W, Shen J, Chen K, Jiang H. A new rapid and effective chemistry space filter in recognizing a druglike database. J Chem Inf Model 2005;45:856-862.
272. Samiulla DS, Vaidyanathan VV, Arun PC, Balan G, Blaze M, Bondre S, et al. Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery. Mol Divers 2005;9:131-139.
273. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-477.
274. Chattopadhyay D. Ethnomedicinal antivirals: Scope and opportunity. In: Ahmad I, Aqil F, Owais M, editors. Modern phytomedicine: Turning medicinal plants into drugs. Weinheim: Wiley-VCH; 2006. pp 313-339.
275. Cos P, Vanden Berghe D, De Bruyne T, Vlietinck AJ. Plant substances as antiviral agents: An update (1997-2001). Curr Org Chem 2003;7:1163-1180.
276. Vlietinck AJ, De Bruyne T, Vanden Berghe DA. Plant substances as antiviral agents. Curr Org Chem 1997;1:307-344.
277. Message SD, Johnston SL. Host defense function of the airway epithelium in health and disease: Clinical background. J Leukocyte Biol 2004;75:5-17.
278. Blumenthal M. Herb sales down 6 percent in mainstream market. Herbal Gram 2005;66:63.
279. Woelkart K, Linde K, Bauer R. Echinacea for preventing and treating the common cold. Planta Med 2008;74:633-637.
280. Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. The Cochrane Database of Systematic Reviews 2006:Issue 1.
281. Shah SA, Sander S, White CM, Rinaldi M, Coleman C. Evaluation of Echinacea for the prevention and treatment of the common cold: A meta-analysis. Lancet Infect Dis 2007;7:473-480.
282. Schoop R, Klein P, Suter A, Johnston SL. Echinacea in the prevention of induced rhinovirus colds: A meta-analysis. Clin Ther 2006;28:174-183.
283. Woelkart K, Bauer R. The role of alkamides as an active principle of Echinacea. Planta Med 2007;73:615-623.
284. Raduner S, Majewska A, Chen J-Z, Xie X-Q, Hamon J, Faller B, Altmann K-H, Gertsch J. Alkylamides from Echinacea are a new class of cannabinomimetics: Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem 2006;281:14192-14206.
285. Dalby-Brown L, Barsett H, Landbo R, Meyer AS, Molgaard P. Synergistic anti-oxidative effects of alkamides, caffeic acid derivatives, and polysaccharide fractions from Echinacea purpurea on in vitro oxidation of human low-density lipoproteins. J Agric Food Chem 2005;53:9413-9423.
286. Sharma M, Arnason JT, Burt A, Hudson JB. Echinacea extracts modulate the pattern of chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial cells. Phytother Res 2006;20:147-152.
287. Altamirano-Dimas M, Hudson JB, Cochrane D, Nelson C, Arnason JT. Modulation of immune response gene expression by echinacea extracts: Results of a gene array analysis. Can J Physiol Pharmacol 2007;85:1091-1098.
288. Josling P. Preventing the common cold with a garlic supplement: A double-blind, placebo-controlled survey. Adv Ther 2001;18:189-193.
289. Weber ND, Andersen DO, North JA, Murray BK, Lawson LD, Hughes BG. In vitro virucidal effects of Allium sativum (garlic) extract and compounds. Planta Med 1992;58:417-423.
290. Burger RA, Warren RP, Lawson LD, Hughes BG. Enhancement of in vitro human immune function by Allium sativum L. (garlic) fractions. Int J Pharmacog 1993;31:169-174.
291. McElhaney Janet E, Goel V, Toane B, Hooten J, Shan Jacqueline J. Efficacy of COLD-fX in the prevention of respiratory symptoms in community-dwelling adults: A randomized, double-blinded, placebo controlled trial. J Altern Complement Med 2006;12:153-157.
292. Predy GN, Goel V, Lovlin R, Donner A, Stitt L, Basu TK. Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: A randomized controlled trial. Can Medic Assoc J 2005;173:1043-1048.
293. Vohra S, Johnston BC, Laycock KL, Midodzi WK, Dhunnoo I, Harris E, Baydala L. Safety and tolerability of North American ginseng extract in the treatment of pediatric upper respiratory tract infection: A phase II randomized, controlled trial of 2 dosing schedules. Pediatrics 2008;122:e402-e410.
294. Cho JY. Inhibitory effect of ginsenoside Rg3 and its derivative ginsenoside Rg3-2H on NO production and lymphocyte proliferation. J Ginseng Res 2008;32:264-269.
295. Biondo PD, Goruk S, Ruth MR, O'Connell E, Field CJ. Effect of CVT-E002 (COLD-fX) versus a ginsenoside extract on systemic and gut-associated immune function. Int Immunopharmacol 2008;8:1134-1142.
296. Bae E-A, Shin J-E, Park S-H, Kim D-H. Inhibitory effect of ginseng polysaccharides on rotavirus infection. J Microbiol Biotechnol 2004;14:202-204.
297. Fukushima Y, Bastow KF, Ohba T, Lee KH. Antiviral activity of dammarane saponins against herpes simplex virus I. Int J Pharmacog 1995;33:2-6.
298. Kuroiwa A, Liou SY, Yan H, Eshita A, Naitoh S, Nagayama A. Effect of a traditional Japanese herbal medicine, Hochu-ekki-to (Bu-Zhong-Yi-Qi Tang), on immunity in elderly persons. Int Immunopharmacol 2004;4:317-324.
299. Iwama H, Amagaya S, Ogihara Y. Effects of five kampohozais on the mitogenic activity of lipopolysaccharide, concanavalin A, phorbol myristate acetate and phytohemagglutinin in vivo. J Ethnopharmacol 1986;18:193-204.
300. Utsuyama M, Seidlar H, Kitagawa M, Hirokawa K. Immunological restoration and anti-tumor effect by Japanese herbal medicine in aged mice. Mech Ageing Dev 2001;122:341-352.
301. Yang S-H, Yu C-L. Antiinflammatory effects of Bu-zhong-yi-qi-tang in patients with perennial allergic rhinitis. J Ethnopharmacol 2008;115:104-109.
302. Yamaya M, Sasaki T, Yasuda H, Inoue D, Suzuki T, Asada M, Yoshida M, Seki T, Iwasaki K, Nishimura H, Nakayama K. Hochu-ekki-to inhibits rhinovirus infection in human tracheal epithelial cells. Br J Pharmacol 2007;150:702-710.
303. Lizogub Viktor G, Riley David S, Heger M. Efficacy of a pelargonium sidoides preparation in patients with the common cold: A randomized, double blind, placebo-controlled clinical trial. Explore-NY 2007;3:573-584.
304. Timmer A, Gunther J, Rucker G, Motschall E, Antes G, Kern Winfried V. Pelargonium sidoides extract for acute respiratory tract infections. The Cochrane Database of Systematic Reviews 2008:Issue 3.
305. Kolodziej H. Traditionally used pelargonium species: Chemistry and biological activity of umckaloabo extracts and their constituents. Curr Top Phytochem 2000;3:77-93.
306. Kolodziej H. Aqueous ethanolic extract of the roots of Pelargonium sidoides-New scientific evidence for an old anti-infective phytopharmaceutical. Planta Med 2008;74:661-666.
307. Schnitzler P, Schneider S, Stintzing FC, Carle R, Reichling J. Efficacy of an aqueous Pelargonium sidoides extract against herpesvirus. Phytomedicine 2008;15:1108-1116.
308. Carlucci MJ, Scolaro LA, Noseda MD, Cerezo AS, Damonte EB. Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice. Antiviral Res 2004;64:137-141.
309. Gonzalez ME, Alarcon B, Carrasco L. Polysaccharides as antiviral agents: Antiviral activity of carrageenan. Antimicrob Agents Chemother 1987;31:1388-1393.
310. Grassauer A, Weinmuellner R, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H. Iota-Carrageenan is a potent inhibitor of rhinovirus infection. Virol J 2008;5:107.
311. Gagnier Joel J, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Recommendations for reporting randomized controlled trials of herbal interventions: Explanation and elaboration. J Clin Epidemiol 2006;59:1134-1149.
312. Farnsworth NR. Ethnopharmacology and drug development. In: Chadwick DJ, Marsh J, editors. Ethnobotany and the search for new drugs: Ciba Foundation Symposium 185. New York: Wiley; 1994. pp 42-59.
313. Heinrich M. Ethnobotany and natural products: The search for new molecules, new treatments of old diseases or a better understanding of indigenous cultures? Curr Top Med Chem 2003;3:141-154.
314. Gertsch J. How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems. J Ethnopharmacol 2009;122:177-183.
315. Beck LYt. Pedanius Dioscorides of Anazarbus-De materia medica. Hildesheim: Olms; 2005.
316. Nassar MI, Abu-Mustafa EA, Ahmed AA. Sesquiterpene coumarins from Ferula assafoetida L. Pharmazie 1995;50:766-767.
317. Semple SJ, Nobbs SF, Pyke SM, Reynolds GD, Flower RLP. Antiviral flavonoid from Pterocaulon sphacelatum, an Australian Aboriginal medicine. J Ethnopharmacol 1999;68:283-288.
318. Rollinger JM, Schuster D, Danzl B, Schwaiger S, Markt P, Schmidtke M, Gertsch J, Raduner S, Wolber G, Langer T, Stuppner H. In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens L. Planta Med 2009;75:195-204.
319. Tsuchiya Y, Shimizu M, Hiyama Y, Itoh K, Hashimoto Y, Nakayama M, Horie T, Morita N. Antiviral activity of natural occurring flavonoids in vitro. Chem Pharm Bull 1985;33:3881-3886.
320. Vanden Berghe DAR, Haemers A, Vlietinck AJ. Antiviral agents from higher plants and example of structure-activity relationship of 3-methoxyflavones. In: Colegate SM, Molyneux RJ, editors. Bioactive Natural Products: Detection, Isolation and Structural Determination. Boca Raton: CRC; 1993. pp 405-440.
321. De Meyer N, Haemers A, Mishra L, Pandey HK, Pieters LAC, Vanden Berghe DA, Vlietinck AJ. 4′-Hydroxy-3-methoxyflavones with potent antipicornavirus activity. J Med Chem 1991;34:736-746.
322. Cragg GM, Newman DJ. Biodiversity: A continuing source of novel drug leads. Pure Appl Chem 2005;77:7-24.
323. Singh SB, Cordingley MG, Ball RG, Smith JL, Dombrowski AW, Goetz MA. Structure and stereochemistry of thysanone: A novel human rhinovirus 3C-protease inhibitor from Thysanophora penicilloides. Tetrahedron Lett 1991;32:5279-5282.
324. Singh SB, Graham PL, Reamer RA, Cordingley MG. Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues. Bioorg Med Chem Lett 2001;11:3143-3146.
325. Choi HJ, Lim CH, Song JH, Baek SH, Kwon DH. Antiviral activity of raoulic acid from Raoulia australis against Picornaviruses. Phytomedicine 2009;16:35-39.
326. Ishitsuka H, Ohsawa C, Ohiwa T, Umeda I, Suhara Y. Antipicornavirus flavone Ro 09-0179. Antimicrob Agents Chemother 1982;22:611-616.
327. Spasova M, Philipov S, Nikolaeva-Glomb L, Galabov AS, Milkova T. Cinnamoyl-and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. Bioorg Med Chem 2008;16:7457-7461.
328. Selway JWT. Antiviral activity of flavones and flavans. Prog Clin Biol Res 1986;213:521-536.
329. Vlietinck AJ, Vanden Berghe DA, Haemers A. Present status and prospects of flavonoids as anti-viral agents. Prog Clin Biol Res 1988;280:283-299.
330. Tisdale M, Selway JWT. Inhibition of an early stage of rhinovirus replication by dichloroflavan (BW683C). J Gen Virol 1983;64:795-803.
331. Tisdale M, Selway JWT. Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type 1B. J Antimicrob Chemother 1984;14:97-105.
332. Al-Nakib W, Willman J, Higgins PG, Tyrrell DA, Shepherd WM, Freestone DS. Failure of intranasally administered 4′, 6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol 1987;92:255-260.
333. Phillpotts RJ, Wallace J, Tyrrell DA, Freestone DS, Shepherd WM. Failure of oral 4′, 6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol 1983;75:115-121.
334. Gasteiger J, Teckentrup A, Terfloth L, Spycher S. Neural networks as data mining tools in drug design. J Phys Org Chem 2003;16:232-245.
335. Xu J, Hagler A. Chemoinformatics and drug discovery. Molecules 2002;7:566-600.
336. Langer T, Hoffmann RD. Pharmacophores and pharmacophore searches. In: Langer T, Hoffmann RD, editors. Methods and principles in medicinal chemistry. Volume 32. Weinheim: Wiley-VCH; 2006.
337. Manly CJ, Louise-May S, Hammer JD. The impact of informatics and computational chemistry on synthesis and screening. Drug Discov Today 2001;6:1101-1110.
338. Kirchmair J, Distinto S, Schuster D, Spitzer G, Langer T, Wolber G. Enhancing drug discovery through in silico screening: Strategies to increase true positives retrieval rates. Curr Med Chem 2008;15:2040-2053.
339. Zupan J, Gasteiger J. Neural networks for chemists. Weinheim: Wiley-VCH; 2000.
340. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000;28:235-242.
341. Kirchmair J, Markt P, Distinto S, Schuster D, Spitzer GM, Liedl KR, Langer T, Wolber G. The Protein Data Bank (PDB), its related services and software tools as key components for in silico guided drug discovery. J Med Chem 2008;51:7021-7040.
342. Kirchmair J, Distinto S, Liedl KR, Markt P, Rollinger JM, Schuster D, Spitzer GM, Wolber G. Development of antiviral agents using molecular modeling and virtual screening techniques. J Infect Dis 2009; in press.
343. Cramer III R, Patterson D, Bunce J. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110:5959-5967.
344. Artico M, Botta M, Corelli F, Mai A, Massa S, Ragno R. Investigation on QSAR and binding mode of a new class of human rhinovirus-14 inhibitors by CoMFA and docking experiments. Bioorg Med Chem 1996;4:1715-1724.
345. Diana GD, Cutcliffe D, Oglesby RC, Otto MJ, Mallamo JP, Akullian V, McKinlay MA. Synthesis and structure-activity studies of some disubstituted phenylisoxazoles against human picornavirus. J Med Chem 1989;32:450-455.
346. Diana GD, Kowalczyk P, Treasurywala AM, Oglesby RC, Pevear DC, Dutko FJ. CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14. J Med Chem 1992;35:1002-1008.
347. Diana GD, Oglesby RC, Akullian V, Carabateas PM, Cutcliffe D, Mallamo JP, Otto MJ, McKinlay MA, Maliski EG, Michalec SJ. Structure-activity studies of 5-[[4-(4, 5-dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles: Inhibitors of picornavirus uncoating. J Med Chem 1987;30:383-388.
348. Verma RP, Hansch C. Understanding human rhinovirus infections in terms of QSAR. Virology 2007;359:152-161.
349. Cheah KC, Leong LEC, Porter AG. Site-directed mutagenesis suggests close functional relationship between a human rhinovirus 3C cysteine protease and cellular trypsin-like serine proteases. J Biol Chem 1990;265:7180-7187.
350. Malcolm BA. The picornaviral 3C proteinases: Cysteine nucleophiles in serine proteinase folds. Protein Sci 1995;4:1439-1445.
351. Reich SH, Johnson T, Wallace MB, Kephart SE, Fuhrman SA, Worland ST, Matthews DA, Hendrickson TF, Chan F, Meador J, Ferre RA, Brown EL, DeLisle DM, Patick AK, Binford SL, Ford CE. Substituted benzamide inhibitors of human rhinovirus 3C protease: Structure-based design, synthesis, and biological evaluation. J Med Chem 2000;43:1670-1683.
352. Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson J-PR, Sakata SK, Chen L, Guzman MC, Meador III JW, Ferre RA, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. J Med Chem 2002;45:1607-1623.
353. Wermuth C-G, Ganellin CR, Lindberg P, Mitscher LA. Glossary of terms used in medicinal chemistry (IUPAC recommendations 1997). Annu Rep Med Chem 1998;33:385-395.
354. Wolber G, Kosara R. Pharmacophores and pharmacophore searches. In: Langer T, Hoffmann RD, editors. Methods and principles in medicinal chemistry. Volume 32. Weinheim: Wiley-VCH; 2006. pp 131-150.
355. Steindl T, Laggner C, Langer T. Human rhinovirus 3C protease: Generation of pharmacophore models for peptidic and nonpeptidic inhibitors and their application in virtual screening. J Chem Inf Model 2005;45:716-724.
356. Steindl T, Langer T. Docking versus pharmacophore model generation: A comparison of high-throughput virtual screening strategies for the search of human rhinovirus coat protein inhibitors. QSAR Comb Sci 2005;24:470-479.
357. Pipeline Pilot. San Diego, CA: Accelrys.
358. Discovery Studio. San Diego, CA: Accelrys.
359. Inte:Ligand Pharmacophore Database. Vienna, Austria: Inte:Ligand.